Extracorporeal photopheresis (ECP) has been in clinical use for over three decades after
receiving FDA approval for the palliative treatment of the Sézary Syndrome variant of …

Extracorporeal photopheresis (ECP) is a cell-based immunotherapy that involves the
reinfusion of autologous leukocytes after exposure to psoralen and UVA. The treatment has …

Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-
methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological …

Extracorporeal phototherapy (ECP) is a therapeutic approach based on the biological effect
of psoralen 8-methoxypsoralen (8-MOP) and ultraviolet light A (UVA) on mononuclear cells …

Extracorporeal photopheresis (ECP) is an autologous cell therapy that is widely used for the
treatment of T cell-mediated diseases. ECP has been FDA-approved for the treatment of …

Extracorporeal photopheresis (ECP) is a well‐tolerated procedure that suppresses T‐
lymphocyte activity in a clonally‐specific way. It is an effective therapy that has established …

Photopheresis or extracorporeal photochemotherapy (ECP) is a novel immunomodulatory
therapy which involves separation of the patient's leucocyte‐rich plasma, followed by ex vivo …

This synopsis reviews recent developments in dermatological phototherapy. UVA1
phototherapy (340-400 nm) is effective in the treatment of inflammatory skin diseases such …

Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of
erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years for chronic and acute …

Extracorporeal photochemotherapy (ECP) was introduced by Edelson and co-workers in
1985. Since then the therapy, though still controversial in specific indications, has received …